Show simple item record

dc.contributor.authorWingelhofer, Bettina
dc.contributor.authorSomervaille, Tim CP
dc.date.accessioned2019-10-07T15:16:45Z
dc.date.available2019-10-07T15:16:45Z
dc.date.issued2019en
dc.identifier.citationWingelhofer B, Somervaille TCP. Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. Front Oncol. 2019;9:850.en
dc.identifier.pmid31552175en
dc.identifier.doi10.3389/fonc.2019.00850en
dc.identifier.urihttp://hdl.handle.net/10541/622216
dc.description.abstractAcute myeloid leukemia (AML) is a genetically heterogeneous malignancy for which treatment options have been largely limited to cytotoxic chemotherapy for the past four decades. Next-generation sequencing and other approaches have identified a spectrum of genomic and epigenomic alterations that contribute to AML initiation and maintenance. The key role of epigenetic modifiers and the reversibility of epigenetic changes have paved the way for evaluation of a new set of drug targets, and facilitated the design of novel candidate treatment strategies. More recently, seven new targeted therapies have been FDA-approved demonstrating successful implementation of the past decades' research. In this review, we will summarize the most recent advances in targeted therapeutics designed for a focused group of key epigenetic regulators in AML, outline their mechanism of action and their current status in clinical development. Furthermore, we will discuss promising new approaches for epigenetic targeted treatment in AML which are currently being tested in pre-clinical trials.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3389/fonc.2019.00850en
dc.titleEmerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemiaen
dc.typeArticleen
dc.contributor.departmentLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchesteren
dc.identifier.journalFrontiers in Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record